---
title: "Weekly Recap | Merck +1.3%, multiple drug wins"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300193396.md"
description: "Merck (MRK) rose 1.3% this week to close at $148.78, slightly ahead of the S&P 500’s 1.21% gain. Trading was choppy. Monday dipped to $145.60 before recovering, Tuesday pushed to a session high of $153.57, then the next three sessions drifted lower to end the week at $148.78. Price hovered around the 20-day moving average of $147.887, with a weekly swing of 5.43%, a touch wider than the 60-day norm."
datetime: "2026-09-26T07:25:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300193396.md)
  - [en](https://longbridge.com/en/news/300193396.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300193396.md)
generator: "portal-rs"
---

# Weekly Recap | Merck +1.3%, multiple drug wins

## The Week

Merck (MRK) rose 1.3% this week to close at $148.78, slightly ahead of the S&P 500’s 1.21% gain. Trading was choppy. Monday dipped to $145.60 before recovering, Tuesday pushed to a session high of $153.57, then the next three sessions drifted lower to end the week at $148.78. Price hovered around the 20-day moving average of $147.887, with a weekly swing of 5.43%, a touch wider than the 60-day norm.

## Key Events

Merck had a dense week of regulatory and clinical news. On Monday, the subcutaneous KEYTRUDA QLEX formulation was approved in Japan, covering all KEYTRUDA indications already approved there. On Tuesday, the FDA approved an update to the WINREVAIR label adding Phase 3 HYPERION trial data in newly diagnosed pulmonary arterial hypertension patients; Merck said the trial showed a 76% reduction in risk of clinical worsening. On Thursday, its investigational eye drug remigromig met the primary endpoint in the pivotal Phase 2B/3 Brunello study in diabetic macular edema, and the company said on Friday the efficacy was at par with Roche’s medicine. Also on Friday, the Welireg plus Lenvima combination with Eisai won FDA approval for kidney cancer. Over the weekend, Merck and Daiichi Sankyo withdrew a US biologics licence application for a lung cancer therapy.

## Analyst Ratings

Of 28 institutions covering Merck, 15 rate it buy, 5 overweight and 8 hold; there are no underweight or sell ratings. The consensus recommendation is buy, with a consensus target of $153.65, roughly 3.3% above the share price of $148.78. Target prices range widely from $105.00 to $186.00, showing clear disagreement. Merck ranks fourth among 203 pharmaceutical stocks in terms of analyst ratings.

## The Week Ahead

Merck has no scheduled earnings this week, with its fiscal Q3 2026 report due before the open on 2026-10-29. On the macro side, the next few days bring the Dallas Fed manufacturing activity index on Monday, and FHFA house prices, Case Shiller home prices, JOLTS job openings and consumer confidence on Tuesday. For Merck itself, this week’s cluster of clinical and regulatory updates could set up further catalysts, particularly the next steps for remigromig in diabetic macular edema after hitting its key endpoint.

## In Short

Merck’s pipeline moved on several fronts this week, with FDA approvals and readouts landing across oncology, cardiovascular and ophthalmology. The analyst backdrop is positive: the majority rate it buy or overweight and the consensus target sits above spot, though the wide target range suggests real disagreement. Valuation is stretched at about 115.68x P/E, and the latest session showed large-lot money as a net seller. The question going forward is whether the development momentum translates into revenue and how the market resolves the tension between high multiples and fund outflows.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [What Is Merck (MRK) Betting On With Its $2.13 Billion KRAS Deal?](https://longbridge.com/en/news/300416193.md)
- [MSD’s Phase IIb study of tulisokibart achieves primary endpoint](https://longbridge.com/en/news/300669336.md)
- [MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor](https://longbridge.com/en/news/300472171.md)
- [Merck says experimental skin disease drug meets main goal in mid-stage study](https://longbridge.com/en/news/300573340.md)
- [MSD to Make USD400 Million Upfront Payment for Global Rights to SciBrunch Cancer Drug](https://longbridge.com/en/news/300378764.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**